Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · IEX Real-Time Price · USD
20.15
-0.88 (-4.18%)
At close: Jul 19, 2024, 4:30 PM
20.19
+0.04 (0.20%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Contineum Therapeutics Revenue
In the year 2023, Contineum Therapeutics had annual revenue of $50.00M.
Revenue (ttm)
$50.00M
Revenue Growth
n/a
P/S Ratio
10.37
Revenue / Employee
$1,612,903
Employees
31
Market Cap
518.32M
Revenue Chart
* The company reports in USD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 50.00M | - | - |
Dec 31, 2022 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCTNM News
- 27 days ago - Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors - Business Wire
- 6 weeks ago - Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference - Business Wire
- 6 weeks ago - Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary - Business Wire
- 2 months ago - Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors - Business Wire
- 2 months ago - Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
- 3 months ago - Contineum Therapeutics Announces Pricing of Initial Public Offering - GlobeNewsWire
- 4 months ago - Neuroscience and inflammation biotech Contineum Therapeutics files for a $150 million IPO - Renaissance Capital
- 4 months ago - Contineum Therapeutics IPO Registration Document (S-1) - SEC